PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10675243-10 2000 In contrast, only inhibition of cytosolic phospholipase A2 led to a decrease in interleukin-1beta-stimulated prostaglandin E2 release. Dinoprostone 109-125 phospholipase A2 group IVA Homo sapiens 32-58 11897617-8 2002 The cPLA(2)-mediated PPAR activation was likely mediated by arachidonic acid and prostaglandin E(2). Dinoprostone 81-99 phospholipase A2 group IVA Homo sapiens 4-10 12664626-0 2002 LPS-induced synthesis and release of PGE2 in liver macrophages: regulation by CPLA2, COX-1, COX-2, and PGE2 synthase. Dinoprostone 37-41 phospholipase A2 group IVA Homo sapiens 78-83 10946311-4 2000 Enhancement of TNF-alpha-stimulated PGE2 production in synovial cells was accompanied by increased expression of cyclooxygenase (COX)-2 and cytosolic phospholipase A2 (cPLA2)-alpha. Dinoprostone 36-40 phospholipase A2 group IVA Homo sapiens 140-166 10946311-4 2000 Enhancement of TNF-alpha-stimulated PGE2 production in synovial cells was accompanied by increased expression of cyclooxygenase (COX)-2 and cytosolic phospholipase A2 (cPLA2)-alpha. Dinoprostone 36-40 phospholipase A2 group IVA Homo sapiens 168-173 10675243-12 2000 Interleukin-1beta-stimulated prostaglandin E2 release appears to be dependent on the activity of cytosolic phospholipase A2. Dinoprostone 29-45 phospholipase A2 group IVA Homo sapiens 97-123 10329351-7 1999 The inclusion of the cPLA2-specific inhibitor arachidonyl trifluoromethyl ketone (AACOCF3) resulted in a concentration-dependent inhibition of PGE2 biosynthesis in WISH cells treated with TNF-alpha (>95 per cent at 2 microM). Dinoprostone 143-147 phospholipase A2 group IVA Homo sapiens 21-26 11729854-11 2000 IL-1 and Ca Ion stimulated PGE2 formation was inhibited by the cPLA2 enzyme inhibitors while LPS stimulated PGE2 production was not inhibited by the cPLA2 inhibitor; but was inhibited by the sPLA2 enzyme inhibitor. Dinoprostone 27-31 phospholipase A2 group IVA Homo sapiens 63-68 10731036-4 2000 The formation of PGE2 is preceded by the phosphorylation of cPLA2 and the expression of cyclooxygenase-2 (Cox-2). Dinoprostone 17-21 phospholipase A2 group IVA Homo sapiens 60-65 10731036-7 2000 These data demonstrate that the activation of p38 MAP kinase elicited by IL-1beta leads to the phosphorylation of cPLA2 and Cox-2 overexpression, allowing rapid synthesis of PGE2 as a prerequisite for bradykinin B2 gene expression in human bronchial smooth muscle cells which could explain the hyperresponsiveness of asthmatic patients to bradykinin. Dinoprostone 174-178 phospholipase A2 group IVA Homo sapiens 114-119 11729854-14 2000 In human intestinal epithelial cells, LPS production of PGE2 proceeds through a pathway associated with sPLA2 generated arachidonic acid while IL-1 stimulated PGE2 is produced by arachidonic acid generated by cPLA2. Dinoprostone 159-163 phospholipase A2 group IVA Homo sapiens 209-214 9603953-9 1998 Both cPLA2, sPLA2s-IIA, and -V were able to supply AA to downstream cyclooxygenase-2 for IL-1-induced prostaglandin E2 biosynthesis. Dinoprostone 102-118 phospholipase A2 group IVA Homo sapiens 5-10 9915849-5 1999 When PLA2 and COX were coexpressed, AA released by cPLA2, sPLA2-IIA and sPLA2-V was converted to PGE2 by both COX-1 and COX-2 during the immediate response and predominantly by COX-2 during the delayed response. Dinoprostone 97-101 phospholipase A2 group IVA Homo sapiens 51-56 9811056-9 1998 The cooperative effects of these 2 cytokines were also observed in the production of PGE2 and the expression of 2 regulatory enzymes in PGE2 production, cPLA2 and COX-2. Dinoprostone 85-89 phospholipase A2 group IVA Homo sapiens 153-158 9761428-6 1998 From the results, it is concluded that activation of MAPK and cytosolic phospholipase A2 is involved in the augmentation of prostaglandin E2 synthesis produced by the medium change. Dinoprostone 124-140 phospholipase A2 group IVA Homo sapiens 62-88 8995534-7 1997 We show a coordinate induction of both cPLA2 and COX-2 mRNA by pro-inflammatory cytokines which correlated with increased PGE2 release. Dinoprostone 122-126 phospholipase A2 group IVA Homo sapiens 39-44 9562240-9 1998 IL-1, but not ceramide induced cPLA2 mRNA and protein expression which corresponded with the initiation of PGE2 synthesis. Dinoprostone 107-111 phospholipase A2 group IVA Homo sapiens 31-36 9169405-3 1997 This increased PGE2 production was mediated by constitutively high expression of 85-kDa cytosolic phospholipase A2 (cPLA2) and cyclooxygenase 2 (COX-2). Dinoprostone 15-19 phospholipase A2 group IVA Homo sapiens 88-114 9169405-3 1997 This increased PGE2 production was mediated by constitutively high expression of 85-kDa cytosolic phospholipase A2 (cPLA2) and cyclooxygenase 2 (COX-2). Dinoprostone 15-19 phospholipase A2 group IVA Homo sapiens 116-121 9371732-2 1997 This occurs via a pathway that involves: (1) the protein kinase C (PKC)-dependent activation of mitogen-activated protein kinase (MAPK); (2) the MAPK-dependent phosphorylation and activation of cytosolic phospholipase A2 (cPLA2) and (3) the utilization of cPLA2-derived arachidonate by the cyclo-oxygenase pathway to produce prostaglandin E2 (PGE2). Dinoprostone 325-341 phospholipase A2 group IVA Homo sapiens 194-220 9371732-2 1997 This occurs via a pathway that involves: (1) the protein kinase C (PKC)-dependent activation of mitogen-activated protein kinase (MAPK); (2) the MAPK-dependent phosphorylation and activation of cytosolic phospholipase A2 (cPLA2) and (3) the utilization of cPLA2-derived arachidonate by the cyclo-oxygenase pathway to produce prostaglandin E2 (PGE2). Dinoprostone 343-347 phospholipase A2 group IVA Homo sapiens 194-220 9247974-0 1997 Enhancement of prostaglandin E2 production by epidermal growth factor requires the coordinate activation of cytosolic phospholipase A2 and cyclooxygenase 2 in human squamous carcinoma A431 cells. Dinoprostone 15-31 phospholipase A2 group IVA Homo sapiens 108-134 9247974-6 1997 These results suggest that EGF augments the production of PGE2 by increasing not only the activity of cPLA2 but also the production of COX-2 in A431 cells. Dinoprostone 58-62 phospholipase A2 group IVA Homo sapiens 102-107 8555249-7 1996 Increased synthesis of cPLA2 correlated well with increased [3H]arachidonic acid release, PGE2 synthesis and lipid peroxidation in epidermis after oxidant or UVB treatment. Dinoprostone 90-94 phospholipase A2 group IVA Homo sapiens 23-28 8874384-0 1996 Interleukin-4, transforming growth factor beta 1, and dexamethasone inhibit superantigen-induced prostaglandin E2-dependent collagenase gene expression through their action on cyclooxygenase-2 and cytosolic phospholipase A2. Dinoprostone 97-113 phospholipase A2 group IVA Homo sapiens 197-223 8874384-1 1996 Signalling via MHC class II in human fibroblast-like synoviocytes selectively induces interstitial collagenase gene expression over its natural inhibitor, the tissue inhibitor of metalloproteinase (TIMP), through a prostaglandin E2 (PGE2)-dependent pathway involving cyclooxygenase-2 (COX-2) and cytosolic phospholipase A2 (cPLA2). Dinoprostone 215-231 phospholipase A2 group IVA Homo sapiens 296-322 8874384-1 1996 Signalling via MHC class II in human fibroblast-like synoviocytes selectively induces interstitial collagenase gene expression over its natural inhibitor, the tissue inhibitor of metalloproteinase (TIMP), through a prostaglandin E2 (PGE2)-dependent pathway involving cyclooxygenase-2 (COX-2) and cytosolic phospholipase A2 (cPLA2). Dinoprostone 215-231 phospholipase A2 group IVA Homo sapiens 324-329 8550611-7 1996 Further, PDGF stimulated the rapid release of arachidonic acid and synthesis of prostaglandin E2 (PGE2) which could be inhibited by a cPLA2 inhibitor (AACOCF3). Dinoprostone 80-96 phospholipase A2 group IVA Homo sapiens 134-139 8550611-7 1996 Further, PDGF stimulated the rapid release of arachidonic acid and synthesis of prostaglandin E2 (PGE2) which could be inhibited by a cPLA2 inhibitor (AACOCF3). Dinoprostone 98-102 phospholipase A2 group IVA Homo sapiens 134-139 8928731-0 1996 Increased synthesis of high-molecular-weight cPLA2 mediates early UV-induced PGE2 in human skin. Dinoprostone 77-81 phospholipase A2 group IVA Homo sapiens 45-50 8928731-3 1996 The 105-kDa cPLA2 was demonstrated to be the critical enzyme in UV-induced PGE2 synthesis and erythema in the first 6 h postirradiation. Dinoprostone 75-79 phospholipase A2 group IVA Homo sapiens 12-17 8928731-6 1996 This increase in cPLA2 synthesis and activation also closely correlated with increased PGE2 synthesis and [3H]arachidonic acid release and was effectively blocked by both an S-oligonucleotide antisense to cPLA2 and methyl arachidonate fluorophosphate, a specific inhibitor of cPLA2. Dinoprostone 87-91 phospholipase A2 group IVA Homo sapiens 17-22 7480804-1 1995 The objective of this study was to examine the expression and activity of cytosolic phospholipase A2 (cPLA2) in relation to prostaglandin E2 (PGE2) synthesis in human amnion-derived WISH cells in response to stimulation by interleukin-1 beta (IL-1 beta). Dinoprostone 124-140 phospholipase A2 group IVA Homo sapiens 74-100 7480804-1 1995 The objective of this study was to examine the expression and activity of cytosolic phospholipase A2 (cPLA2) in relation to prostaglandin E2 (PGE2) synthesis in human amnion-derived WISH cells in response to stimulation by interleukin-1 beta (IL-1 beta). Dinoprostone 124-140 phospholipase A2 group IVA Homo sapiens 102-107 7480804-1 1995 The objective of this study was to examine the expression and activity of cytosolic phospholipase A2 (cPLA2) in relation to prostaglandin E2 (PGE2) synthesis in human amnion-derived WISH cells in response to stimulation by interleukin-1 beta (IL-1 beta). Dinoprostone 142-146 phospholipase A2 group IVA Homo sapiens 74-100 7480804-1 1995 The objective of this study was to examine the expression and activity of cytosolic phospholipase A2 (cPLA2) in relation to prostaglandin E2 (PGE2) synthesis in human amnion-derived WISH cells in response to stimulation by interleukin-1 beta (IL-1 beta). Dinoprostone 142-146 phospholipase A2 group IVA Homo sapiens 102-107 7480804-5 1995 Incubation of the cells with 10 microM AACOCF3 for 24 h significantly inhibited IL-1 beta-induced PGE2 production strongly suggesting that cPLA2 mediates IL-1 beta-induced PGE2 formation. Dinoprostone 98-102 phospholipase A2 group IVA Homo sapiens 139-144 7480804-5 1995 Incubation of the cells with 10 microM AACOCF3 for 24 h significantly inhibited IL-1 beta-induced PGE2 production strongly suggesting that cPLA2 mediates IL-1 beta-induced PGE2 formation. Dinoprostone 172-176 phospholipase A2 group IVA Homo sapiens 139-144 7480804-6 1995 In unstimulated cells, there is appreciable total cellular cPLA2 activity and protein, but these cells produce low amounts of PGE2 until stimulated by IL-1 beta, suggesting that cPLA2 translocation from cytosol to the membrane is necessary for its bioactivity. Dinoprostone 126-130 phospholipase A2 group IVA Homo sapiens 178-183 8531498-8 1995 Results suggest that bradykinin stimulates PTSMC to produce PGE2 via the signal transduction system including Ca2+, and dexamethasone appeared to suppress PGE2 production by reducing the activity of cytosolic phospholipase A2 (cPLA2) and PGE2 synthase. Dinoprostone 155-159 phospholipase A2 group IVA Homo sapiens 199-225 7957239-2 1994 In order to identify the enzymes that are linked to IL-1-mediated arachidonate availability and subsequent PGE2 production, we have investigated the changes in gene expression of the 85-kDa cytosolic PLA2 (cPLA2), the 14-kDa secretory PLA2 (sPLA2) and the two forms of cyclooxygenase in human synoviocytes after stimulation with recombinant IL-1 beta. Dinoprostone 107-111 phospholipase A2 group IVA Homo sapiens 206-211 7957239-7 1994 Our data suggest that the IL-1-induced production of PGE2 in human synoviocytes can be attributed to the stimulation of both cPLA2 and cyclooxygenase-2. Dinoprostone 53-57 phospholipase A2 group IVA Homo sapiens 125-130 7957239-0 1994 Interleukin-1-induced prostaglandin E2 biosynthesis in human synovial cells involves the activation of cytosolic phospholipase A2 and cyclooxygenase-2. Dinoprostone 22-38 phospholipase A2 group IVA Homo sapiens 103-129 35089606-9 2022 Molecular analyses linked ATF6alpha regulation of ferroptosis to the PLA2G4A-mediated release of AA and the resulting increase in PGE2 production, the latter of which acts as an antiferroptotic factor. Dinoprostone 130-134 phospholipase A2 group IVA Homo sapiens 69-76 1429687-1 1992 Treatment of the human lung fibroblast cell line, WI-38, with interleukin-1 alpha (IL-1 alpha) results in a large increase in the production of cytosolic phospholipase A2 (cPLA2) and prostaglandin E2 (PGE2). Dinoprostone 201-205 phospholipase A2 group IVA Homo sapiens 172-177 1429687-2 1992 The IL-1-induced accumulation of cPLA2 is closely correlated with increased PGE2 release. Dinoprostone 76-80 phospholipase A2 group IVA Homo sapiens 33-38 26183771-5 2015 Absence of cPLA2alpha almost abolished eicosanoid synthesis in platelets (e.g., thromboxane A2, control 20.5 +- 1.4 ng/ml vs. patient 0.1 ng/ml) and leukocytes [e.g., prostaglandin E2 (PGE2), control 21.9 +- 7.4 ng/ml vs. patient 1.9 ng/ml], and this was associated with impaired platelet activation and enhanced inflammatory responses. Dinoprostone 167-183 phospholipase A2 group IVA Homo sapiens 11-21 26183771-5 2015 Absence of cPLA2alpha almost abolished eicosanoid synthesis in platelets (e.g., thromboxane A2, control 20.5 +- 1.4 ng/ml vs. patient 0.1 ng/ml) and leukocytes [e.g., prostaglandin E2 (PGE2), control 21.9 +- 7.4 ng/ml vs. patient 1.9 ng/ml], and this was associated with impaired platelet activation and enhanced inflammatory responses. Dinoprostone 185-189 phospholipase A2 group IVA Homo sapiens 11-21 34729107-0 2021 Anticancer Effects of Helminthostachys zeylanica Ethyl acetate Extracts on Human Gastric Cancer Cells through Downregulation of the TNF-alpha-activated COX-2-cPLA2-PGE2 Pathway. Dinoprostone 164-168 phospholipase A2 group IVA Homo sapiens 158-163 34729107-9 2021 The anticancer effects of H. zeylanica-E2 in GC cells might be mediated partly through inhibition of tumor necrosis factor-alpha (TNF-alpha)-activated proinflammatory cytosolic phospholipase A2 (cPLA2)-COX-2-prostaglandin E2 (PGE2) pathway. Dinoprostone 208-224 phospholipase A2 group IVA Homo sapiens 195-200 34729107-9 2021 The anticancer effects of H. zeylanica-E2 in GC cells might be mediated partly through inhibition of tumor necrosis factor-alpha (TNF-alpha)-activated proinflammatory cytosolic phospholipase A2 (cPLA2)-COX-2-prostaglandin E2 (PGE2) pathway. Dinoprostone 226-230 phospholipase A2 group IVA Homo sapiens 195-200 34246631-5 2021 Such sustained p38 MAPK activation increases the activity of cytosolic phospholipase A2 (cPLA2), which catalyzes the release of arachidonic acid, the initial substrate for PGE2 biosynthesis. Dinoprostone 172-176 phospholipase A2 group IVA Homo sapiens 61-87 34246631-5 2021 Such sustained p38 MAPK activation increases the activity of cytosolic phospholipase A2 (cPLA2), which catalyzes the release of arachidonic acid, the initial substrate for PGE2 biosynthesis. Dinoprostone 172-176 phospholipase A2 group IVA Homo sapiens 89-94 34246631-7 2021 Restoration of STEP function with a STEP mimetic (TAT-STEP-myc peptide) significantly decreases the activation of p38-MAPK-mediated cPLA2/COX-2/PGE2 signaling cascade. Dinoprostone 144-148 phospholipase A2 group IVA Homo sapiens 132-137 8273584-4 1993 These findings support that an augmentation of CPLA2 activity, caused by an induction of cPLA2 protein, rather than sPLA2, is temporally associated with increased PGE2 production in IL-1 beta-treated RSF. Dinoprostone 163-167 phospholipase A2 group IVA Homo sapiens 47-52 8273584-4 1993 These findings support that an augmentation of CPLA2 activity, caused by an induction of cPLA2 protein, rather than sPLA2, is temporally associated with increased PGE2 production in IL-1 beta-treated RSF. Dinoprostone 163-167 phospholipase A2 group IVA Homo sapiens 89-94 1575744-6 1992 These findings demonstrate that an elevation in a cytosolic PLA2, rather than a sPLA2, is associated with increased PGE2 production in IL-1 beta stimulated RSF. Dinoprostone 116-120 phospholipase A2 group IVA Homo sapiens 50-64 12907132-6 2003 Macrolide antibiotics inhibited PGE2 synthesis in human leukocytes by suppressing cPLA2, COX-1, and COX-2 mRNA expression. Dinoprostone 32-36 phospholipase A2 group IVA Homo sapiens 82-87 34206390-6 2021 BmooMPalpha-I-induced PGE2 biosynthesis was dependent on group-IIA-secreted phospholipase A2 (sPLA2-IIA), cytosolic phospholipase A2-alpha (cPLA2-alpha), and cyclooxygenase (COX)-1 and -2 pathways. Dinoprostone 22-26 phospholipase A2 group IVA Homo sapiens 140-151 33247192-6 2020 Weak acid-induced PGE2 production was significantly inhibited by cytosolic phospholipase A2 (cPLA2), ERK, and transient receptor potential cation channel subfamily V member 4 (TRPV4), a pH-sensing ion channel, inhibitors. Dinoprostone 18-22 phospholipase A2 group IVA Homo sapiens 93-98 33255269-7 2020 The MT-III-induced PGE2 biosynthesis was dependent on cytosolic PLA2 (cPLA2)-alpha, cyclooxygenases (COX)-1 and COX-2 pathways and regulated by a positive loop via the EP4 receptor. Dinoprostone 19-23 phospholipase A2 group IVA Homo sapiens 54-82 31492557-15 2019 ANXA10 promoted the progression of PHCCA and facilitated metastasis by promoting the EMT process via the PLA2G4A/PGE2/STAT3 pathway. Dinoprostone 113-117 phospholipase A2 group IVA Homo sapiens 105-112 33247192-8 2020 These results indicated that weak acids induce PGE2 production via TRPV4/ERK/cPLA2 in oesophageal epithelial cells, suggesting a role in GERD symptoms like heartburn. Dinoprostone 47-51 phospholipase A2 group IVA Homo sapiens 77-82 32879137-5 2020 Further, we identify that COX-2/PGE2 production in wound macrophages requires epigenetic regulation of 2 key enzymes in the cytosolic phospholipase A2/COX-2/PGE2 (cPLA2/COX-2/PGE2) pathway. Dinoprostone 32-36 phospholipase A2 group IVA Homo sapiens 124-150 32879137-5 2020 Further, we identify that COX-2/PGE2 production in wound macrophages requires epigenetic regulation of 2 key enzymes in the cytosolic phospholipase A2/COX-2/PGE2 (cPLA2/COX-2/PGE2) pathway. Dinoprostone 32-36 phospholipase A2 group IVA Homo sapiens 163-168 32879137-5 2020 Further, we identify that COX-2/PGE2 production in wound macrophages requires epigenetic regulation of 2 key enzymes in the cytosolic phospholipase A2/COX-2/PGE2 (cPLA2/COX-2/PGE2) pathway. Dinoprostone 157-161 phospholipase A2 group IVA Homo sapiens 124-150 32879137-5 2020 Further, we identify that COX-2/PGE2 production in wound macrophages requires epigenetic regulation of 2 key enzymes in the cytosolic phospholipase A2/COX-2/PGE2 (cPLA2/COX-2/PGE2) pathway. Dinoprostone 157-161 phospholipase A2 group IVA Homo sapiens 163-168 32879137-5 2020 Further, we identify that COX-2/PGE2 production in wound macrophages requires epigenetic regulation of 2 key enzymes in the cytosolic phospholipase A2/COX-2/PGE2 (cPLA2/COX-2/PGE2) pathway. Dinoprostone 157-161 phospholipase A2 group IVA Homo sapiens 124-150 32879137-5 2020 Further, we identify that COX-2/PGE2 production in wound macrophages requires epigenetic regulation of 2 key enzymes in the cytosolic phospholipase A2/COX-2/PGE2 (cPLA2/COX-2/PGE2) pathway. Dinoprostone 157-161 phospholipase A2 group IVA Homo sapiens 163-168 32620771-8 2020 Treatment with cPLA2-alpha inhibitor (CAY10650) or DGAT-1 inhibitor (A922500) suppressed lipid droplets formation and PGE2 secretion. Dinoprostone 118-122 phospholipase A2 group IVA Homo sapiens 15-26 33247192-6 2020 Weak acid-induced PGE2 production was significantly inhibited by cytosolic phospholipase A2 (cPLA2), ERK, and transient receptor potential cation channel subfamily V member 4 (TRPV4), a pH-sensing ion channel, inhibitors. Dinoprostone 18-22 phospholipase A2 group IVA Homo sapiens 65-91 33023184-4 2020 We demonstrated that inhibition of cPLA2alpha using AVX001 produced a balanced reduction of prostaglandins and leukotrienes; significantly limited prostaglandin E2 (PGE2) release from both PBMC and HaCaT in response to pro-inflammatory stimuli; attenuated growth factor-induced arachidonic acid and PGE2 release from HaCaT; and inhibited keratinocyte proliferation in the absence and presence of exogenous growth factors, as well as in stratified cultures. Dinoprostone 147-163 phospholipase A2 group IVA Homo sapiens 35-45 33023184-4 2020 We demonstrated that inhibition of cPLA2alpha using AVX001 produced a balanced reduction of prostaglandins and leukotrienes; significantly limited prostaglandin E2 (PGE2) release from both PBMC and HaCaT in response to pro-inflammatory stimuli; attenuated growth factor-induced arachidonic acid and PGE2 release from HaCaT; and inhibited keratinocyte proliferation in the absence and presence of exogenous growth factors, as well as in stratified cultures. Dinoprostone 165-169 phospholipase A2 group IVA Homo sapiens 35-45 33023184-4 2020 We demonstrated that inhibition of cPLA2alpha using AVX001 produced a balanced reduction of prostaglandins and leukotrienes; significantly limited prostaglandin E2 (PGE2) release from both PBMC and HaCaT in response to pro-inflammatory stimuli; attenuated growth factor-induced arachidonic acid and PGE2 release from HaCaT; and inhibited keratinocyte proliferation in the absence and presence of exogenous growth factors, as well as in stratified cultures. Dinoprostone 299-303 phospholipase A2 group IVA Homo sapiens 35-45 31492557-8 2019 The effect of PLA2G4A downstream signaling, including Cyclooxygenase 2, Prostaglandin E2(PGE2) and Signal transducer and activator of transcription 3(STAT3), on EMT and metastasis was further detected with in vitro and in vivo experiments. Dinoprostone 72-88 phospholipase A2 group IVA Homo sapiens 14-21 31492557-16 2019 ANXA10, PLA2G4A and their downstream molecules, such as COX2 and PGE2, may be promising drug targets of PHCCA and DCCA. Dinoprostone 65-69 phospholipase A2 group IVA Homo sapiens 8-15 28690034-8 2017 cPLA2/PGE2 had a role in activating NF-kappaB and CREB DNA-binding activities and inflammatory cytokine transcription via the EP2/cAMP/PKA mechanism in an autocrine loop. Dinoprostone 6-10 phospholipase A2 group IVA Homo sapiens 0-5 30122655-7 2018 DCA acts via its receptor, farnesoid X receptor, to inhibit the enzyme cPLA2 required for PGE2 synthesis. Dinoprostone 90-94 phospholipase A2 group IVA Homo sapiens 71-76 28651842-9 2017 These data show that SDX protects HREC from HG damage and suggest that it counteracts the activation of ERK/cPLA2/COX-2/PGE2 pathway by reducing AGE-related signaling and downstream NFkappaB activity. Dinoprostone 120-124 phospholipase A2 group IVA Homo sapiens 108-113 28188254-6 2017 Consistent with the activation of these inflammatory mediators, OT led to increases in the expression of cyclooxygenase-2 and phosphorylated cytosolic phospholipase A2, which was reflected in prostaglandin E2 synthesis. Dinoprostone 192-208 phospholipase A2 group IVA Homo sapiens 141-167 28042832-3 2016 Here, we show that R-flurbiprofen acts through a dual mechanism: (i) it inhibits the translocation of cPLA2alpha to the plasma membrane and thereby curtails the availability of arachidonic acid and (ii) R-flurbiprofen traps PGE2 inside of the cells by inhibiting multidrug resistance-associated protein 4 (MRP4, ABCC4), which acts as an outward transporter for prostaglandins. Dinoprostone 224-228 phospholipase A2 group IVA Homo sapiens 102-112 28007986-8 2017 The novel phenotype of our patients segregated with a homozygous loss-of-function sequence variant, causing the substitution of leucine at position 752 to phenylalanine, in PLAA, which causes disruption of the protein"s ability to induce prostaglandin E2 and cytosolic phospholipase A2 synthesis in patients" fibroblasts. Dinoprostone 238-254 phospholipase A2 group IVA Homo sapiens 259-285 27554058-7 2016 These data suggest that cPLA2alpha may play a key role in renal repair after injury through a PGE2-independent mechanism. Dinoprostone 94-98 phospholipase A2 group IVA Homo sapiens 24-34 27932980-3 2016 We found that TNF-alpha-stimulated increases in cPLA2 mRNA (5.2 folds) and protein (3.9 folds) expression, promoter activity (4.3 folds), and PGE2 secretion (4.7 folds) in HPAEpiCs, determined by Western blot, real-time PCR, promoter activity assay and PGE2 ELISA kit. Dinoprostone 253-257 phospholipase A2 group IVA Homo sapiens 48-53 26389963-5 2015 In synaptosomes PGE2 increased concentrations of cyclic adenosine monophosphate (cAMP) which suppressed the activation of cPLA2 demonstrating an inhibitory feedback system. Dinoprostone 16-20 phospholipase A2 group IVA Homo sapiens 122-127 26389963-6 2015 Thus, Abeta/alphaSN-induced activated cPLA2 produces PGE2 which increases cAMP which in turn suppresses cPLA2 and, hence, its own production. Dinoprostone 53-57 phospholipase A2 group IVA Homo sapiens 38-43 26389963-6 2015 Thus, Abeta/alphaSN-induced activated cPLA2 produces PGE2 which increases cAMP which in turn suppresses cPLA2 and, hence, its own production. Dinoprostone 53-57 phospholipase A2 group IVA Homo sapiens 104-109 19948080-7 2010 We conclude that the inhibitory effect of ellagic acid on PGE2 release from monocytes is due to a suppressed expression of COX-2, mPGEs-1 and cPLA2alpha, rather than a direct effect on the activities of these enzymes. Dinoprostone 58-62 phospholipase A2 group IVA Homo sapiens 142-152 24349530-4 2013 METHODS: The involvement of cPLA2alpha in tumor necrosis factor (TNF)-induced intracellular signaling cascades in synoviocytes (synovial fibroblast-like cells) was analyzed by arachidonic acid (AA) release assay, synoviocyte enzyme activity assay, gene expression analysis by real-time PCR and ELISA immunoassay for the detection of prostaglandin E2 (PGE2), interleukin 8 (IL8) and stromelysin-1 (MMP3), respectively. Dinoprostone 333-349 phospholipase A2 group IVA Homo sapiens 28-38 23766266-8 2013 We find that LL-37 acts on endothelial cells as a potent calcium agonist, inducing phosphorylation and activation of cytosolic phospholipase A2 (cPLA2), promoting a cPLA2 COX-1 PGE2 biosynthetic pathway and subsequent signaling via PGE2 receptor EP3. Dinoprostone 177-181 phospholipase A2 group IVA Homo sapiens 165-170 24101387-8 2013 NF-kappaB and MAPK cascades-activated transcription factor activator protein 1 (AP-1) and CREB-binding protein (CBP/p300) lead to expression of cytosolic phospholipase A2 (cPLA2), cyclooxygenase-2 (COX-2) and membrane-bound prostaglandin E synthase 1 (mPGES-1), and thus to increased release of arachidonic acid and production of prostaglandins, particularly prostaglandin E2 (PGE2). Dinoprostone 359-375 phospholipase A2 group IVA Homo sapiens 144-170 24101387-8 2013 NF-kappaB and MAPK cascades-activated transcription factor activator protein 1 (AP-1) and CREB-binding protein (CBP/p300) lead to expression of cytosolic phospholipase A2 (cPLA2), cyclooxygenase-2 (COX-2) and membrane-bound prostaglandin E synthase 1 (mPGES-1), and thus to increased release of arachidonic acid and production of prostaglandins, particularly prostaglandin E2 (PGE2). Dinoprostone 359-375 phospholipase A2 group IVA Homo sapiens 172-177 24101387-8 2013 NF-kappaB and MAPK cascades-activated transcription factor activator protein 1 (AP-1) and CREB-binding protein (CBP/p300) lead to expression of cytosolic phospholipase A2 (cPLA2), cyclooxygenase-2 (COX-2) and membrane-bound prostaglandin E synthase 1 (mPGES-1), and thus to increased release of arachidonic acid and production of prostaglandins, particularly prostaglandin E2 (PGE2). Dinoprostone 377-381 phospholipase A2 group IVA Homo sapiens 144-170 24101387-8 2013 NF-kappaB and MAPK cascades-activated transcription factor activator protein 1 (AP-1) and CREB-binding protein (CBP/p300) lead to expression of cytosolic phospholipase A2 (cPLA2), cyclooxygenase-2 (COX-2) and membrane-bound prostaglandin E synthase 1 (mPGES-1), and thus to increased release of arachidonic acid and production of prostaglandins, particularly prostaglandin E2 (PGE2). Dinoprostone 377-381 phospholipase A2 group IVA Homo sapiens 172-177 22831644-2 2012 EXPERIMENTAL APPROACH: Here we report on two new cPLA(2) inhibitors, the omega3-derivatives AVX001 and AVX002, and their effects on inflammatory PGE(2) production in cultures of renal mesangial cells. Dinoprostone 146-152 phospholipase A2 group IVA Homo sapiens 49-56 22696602-11 2012 In conclusion, FSS activates cPLA2 to generate PGE(2) that regulates flow-mediated Na and K transport in the native CD. Dinoprostone 47-53 phospholipase A2 group IVA Homo sapiens 29-34 22673578-4 2012 Human CG triggered robust ovarian prostaglandin (PG) E(2) production in the preovulatory period that was significantly attenuated in Pla2g4a(-/-) mice. Dinoprostone 34-57 phospholipase A2 group IVA Homo sapiens 133-140 22227093-7 2012 Furthermore, the prostaglandin E(2) (PGE(2)) regulatory enzyme cytosolic phospholipase A(2) (cPLA(2)) and the anti-inflammatory prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), were found to regulate TLR2 mRNA expression stimulated by TNFalpha. Dinoprostone 17-35 phospholipase A2 group IVA Homo sapiens 63-100 21702012-12 2011 Up-regulation of cPLA2 by IL-1beta increased PGE(2) biosynthesis in RASFs. Dinoprostone 45-51 phospholipase A2 group IVA Homo sapiens 17-22 20227521-11 2010 Considering that PGE(2) is a potent promoter of cancer cell proliferation and survival, understanding the mechanism coupling cPLA(2)alpha with COX-1 is of potential clinical significance. Dinoprostone 17-23 phospholipase A2 group IVA Homo sapiens 125-137 26081696-7 2015 The results of the present study demonstrated that elevation in the ratio of AA to PGE2 via suppression of the protein expression of cPLA2 and COX-2 in the AA metabolic pathway is involved in the inhibitory effect of BBR in HCC. Dinoprostone 83-87 phospholipase A2 group IVA Homo sapiens 133-138 25893499-7 2015 Activation of TLR2/1 and TLR2/6 led to phosphorylation of cPLA2alpha at Ser505, and induced AA release and PGE2 production; effects that were attenuated by cPLA2alpha inhibitors. Dinoprostone 107-111 phospholipase A2 group IVA Homo sapiens 156-166 25893499-11 2015 Moreover, exogenously PGE2 added alone induced IL-6 production and completely rescued IL-6 transcription when added simultaneously with FSL-1 in the presence of a cPLA2alpha inhibitor. Dinoprostone 22-26 phospholipase A2 group IVA Homo sapiens 163-173 25893499-12 2015 Our results demonstrate for the first time that cPLA2alpha is involved in TLR2/1- and TLR2/6-induced AA release, PGE2 production and pro-inflammatory cytokine expression in synoviocytes, possibly through COX/PGE2-dependent pathways. Dinoprostone 113-117 phospholipase A2 group IVA Homo sapiens 48-58 25893499-12 2015 Our results demonstrate for the first time that cPLA2alpha is involved in TLR2/1- and TLR2/6-induced AA release, PGE2 production and pro-inflammatory cytokine expression in synoviocytes, possibly through COX/PGE2-dependent pathways. Dinoprostone 208-212 phospholipase A2 group IVA Homo sapiens 48-58 24441870-11 2014 The activity of cPLA2 protein upregulated by TNF-alpha was reflected on the PGE2 release, which was reduced by AG490, AG1296, LY294002, or PD98059. Dinoprostone 76-80 phospholipase A2 group IVA Homo sapiens 16-21 24170779-4 2014 The biosynthesis of eicosanoids includes as the first step the Ca(2+)- and kinase-dependent activation of the cytosolic phospholipase A2, which releases arachidonic acid from membrane phospholipids, and later events depending on the transcriptional regulation of the enzymes of the cyclooxygenase routes, where PGE2 is the most relevant product. Dinoprostone 311-315 phospholipase A2 group IVA Homo sapiens 110-136 24363440-13 2014 Also, Ucn1 increased the production of prostaglandin E2 (PGE2) which further activated protein kinase A (PKA)-CREB pathways dependent of cPLA2 via CRHR2. Dinoprostone 39-55 phospholipase A2 group IVA Homo sapiens 137-142 24363440-13 2014 Also, Ucn1 increased the production of prostaglandin E2 (PGE2) which further activated protein kinase A (PKA)-CREB pathways dependent of cPLA2 via CRHR2. Dinoprostone 57-61 phospholipase A2 group IVA Homo sapiens 137-142 24363440-15 2014 In conclusion, these data indicate that Ucn1 increase the ICAM1 expression via cPLA2-NF-kappaB and cPLA2-COX2-PGE2-PKA-CREB pathways by means of CRHR2. Dinoprostone 110-114 phospholipase A2 group IVA Homo sapiens 99-104 24349530-4 2013 METHODS: The involvement of cPLA2alpha in tumor necrosis factor (TNF)-induced intracellular signaling cascades in synoviocytes (synovial fibroblast-like cells) was analyzed by arachidonic acid (AA) release assay, synoviocyte enzyme activity assay, gene expression analysis by real-time PCR and ELISA immunoassay for the detection of prostaglandin E2 (PGE2), interleukin 8 (IL8) and stromelysin-1 (MMP3), respectively. Dinoprostone 351-355 phospholipase A2 group IVA Homo sapiens 28-38 24349530-5 2013 RESULTS: Inhibitors of cPLA2alpha enzyme activity (AVX002, ATK) significantly reduced TNF-induced cellular release of AA, PGE2, IL8 and MMP3. Dinoprostone 122-126 phospholipase A2 group IVA Homo sapiens 23-33 24349530-7 2013 Interestingly, cPLA2alpha inhibition affected several key points of the arachidonyl cascade; AA-release, cyclooxygenase-2 (COX2) expression and PGE2 production. Dinoprostone 144-148 phospholipase A2 group IVA Homo sapiens 15-25 24349530-9 2013 CONCLUSIONS: cPLA2alpha appears to be an important regulator of central effectors of inflammation and joint destruction, namely MMP3, IL8, COX2, and PGE2. Dinoprostone 149-153 phospholipase A2 group IVA Homo sapiens 13-23 20850495-8 2011 Taken together, our results indicate that 1 muM Pb2+ can induce PGE2 secretion by upregulating the transcription of COX-2/cPLA2 genes. Dinoprostone 64-68 phospholipase A2 group IVA Homo sapiens 122-127 20379791-4 2010 Secretion of PGE2 was associated with induction of cPLA2 activity and protein content as well as COX-2 protein level in a Src phosphorylation-dependent manner that occurred by enhanced transcription. Dinoprostone 13-17 phospholipase A2 group IVA Homo sapiens 51-56 20410594-10 2010 These results suggest that Orento decreased PGE(2) production by inhibition of cPLA(2) phosphorylation and its activation via inhibition of ERK phosphorylation, and also that Orento may be useful to improve gingival inflammation in periodontal disease. Dinoprostone 44-50 phospholipase A2 group IVA Homo sapiens 79-86 20307736-7 2010 A cPLA(2) inhibitor attenuated both the cytokine-stimulated PGE(2) release as well as changes in osteoclast differentiation-related genes like RANKL. Dinoprostone 60-66 phospholipase A2 group IVA Homo sapiens 2-9 18029351-2 2008 Cytosolic phospholipase A(2)alpha (cPLA(2)alpha) is the rate-limiting key enzyme that cleaves arachidonic acid (AA) from membrane phospholipids for the biosynthesis of eicosanoids, including prostaglandin E(2) (PGE(2)), a key lipid mediator involved in inflammation and carcinogenesis. Dinoprostone 191-209 phospholipase A2 group IVA Homo sapiens 35-47 19847291-9 2009 This was concomitant with increased IL-8 synthesis and cPLA2alpha activation, ultimately resulting in eicosanoid (PGE2 and LTB4) overproduction. Dinoprostone 114-118 phospholipase A2 group IVA Homo sapiens 55-65 19087588-7 2008 The highest levels of COX-2 and mPGES-1 were shown after 16 h treatment by Pg-LPS, or after 8 h and 16 h by Ec-LPS respectively.cPLA2 inhibitor AACOCF3 could lower the level of LPS-induced release of AA, while it did not influence the production of PGE2. Dinoprostone 249-253 phospholipase A2 group IVA Homo sapiens 128-133 16966336-6 2006 Furthermore, PPARdelta activation or PGE2 treatment induced the phosphorylation of cytosolic phospholipase A2alpha (cPLA2alpha), a key enzyme that releases arachidonic acid (AA) substrate for PG production via COX. Dinoprostone 37-41 phospholipase A2 group IVA Homo sapiens 116-126 16458424-0 2006 Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production. Dinoprostone 136-152 phospholipase A2 group IVA Homo sapiens 0-28 16458424-7 2006 Both cPLA2 and COX-2 expressions are important in regard to PGE2 production. Dinoprostone 60-64 phospholipase A2 group IVA Homo sapiens 5-10 17643350-2 2007 We found that the Ca2+-dependent type IV cytosolic phospholipase A2 (cPLA2) was pivotally involved in the COX-2-mediated generation of PGE2 in response to a calcium ionophore, as determined by the use of selected PLA2 inhibitors. Dinoprostone 135-139 phospholipase A2 group IVA Homo sapiens 41-67 17643350-2 2007 We found that the Ca2+-dependent type IV cytosolic phospholipase A2 (cPLA2) was pivotally involved in the COX-2-mediated generation of PGE2 in response to a calcium ionophore, as determined by the use of selected PLA2 inhibitors. Dinoprostone 135-139 phospholipase A2 group IVA Homo sapiens 69-74 17643350-3 2007 PGE2 biosynthesis elicited by bacterial-derived peptides or by phagocytic stimuli acting on cell surface receptors also showed to be dependent on cPLA2 activity. Dinoprostone 0-4 phospholipase A2 group IVA Homo sapiens 146-151 16675300-6 2006 The delayed synthesis of PGE2 and PGF2alpha following the stimulation for 24 with a mixture of PMA and calcium ionophore A23187 was the highest in preadipocytes, reflecting the increased expression levels of cPLA2alpha and COX-2. Dinoprostone 25-29 phospholipase A2 group IVA Homo sapiens 208-218 16966336-9 2006 In contrast, although PGE2 treatment increased the DRE reporter activity in intact cells, it failed to induce PPARdelta binding to DRE in cell-free system, suggesting that cPLA2alpha-mediated AA release is required for PGE2-induced PPARdelta activation. Dinoprostone 219-223 phospholipase A2 group IVA Homo sapiens 172-182 16966336-10 2006 Taken together, these observations reveal that PPARdelta induces COX-2 expression in human cholangiocarcinoma cells and that the COX-2-derived PGE2 further activates PPARdelta through phosphorylation of cPLA2alpha. Dinoprostone 143-147 phospholipase A2 group IVA Homo sapiens 203-213 16741257-0 2006 Polyamine-mediated reduction in human airway epithelial migration in response to wounding is PGE2 dependent through decreases in COX-2 and cPLA2 protein levels. Dinoprostone 93-97 phospholipase A2 group IVA Homo sapiens 139-144 16859643-3 2006 In terms of the downstream signalings triggered by WKYMVm and SAA, both agonists stimulated cytosolic phospholipase A2-mediated arachidonic acid release, a precursor of leukotriene B4 (LTB4) and prostaglandin E2 (PGE2). Dinoprostone 195-211 phospholipase A2 group IVA Homo sapiens 92-118 16859643-3 2006 In terms of the downstream signalings triggered by WKYMVm and SAA, both agonists stimulated cytosolic phospholipase A2-mediated arachidonic acid release, a precursor of leukotriene B4 (LTB4) and prostaglandin E2 (PGE2). Dinoprostone 213-217 phospholipase A2 group IVA Homo sapiens 92-118 16709925-9 2006 PGE2 formed via cPLA2 activates CREB through PKA and this process is dependent on development of PGE2 receptor 4. Dinoprostone 0-4 phospholipase A2 group IVA Homo sapiens 16-21 15242810-8 2004 Therefore, these results suggest that nobiletin inhibits the UVB-induced production of PGE2 not only by suppressing the expression of COX-2 but also by decreasing the activity of cPLA2 in human keratinocytes. Dinoprostone 87-91 phospholipase A2 group IVA Homo sapiens 179-184 16120814-9 2005 We conclude that PAR(2)-triggered PGE(2) formation in A549 cells involves a coordinated up-regulation of COX-2 and mPGES-1 involving cPLA(2), increased cytosolic Ca(2+), PKC, Src, MEK-ERK, p38 MAPK, Src-mediated EGF receptor trans-activation, and also metabolic products of both COX-1 and COX-2. Dinoprostone 34-40 phospholipase A2 group IVA Homo sapiens 133-140 15972573-12 2005 A cPLA2-selective inhibitor decreased both PLA2 activity in monkey granulosa cell lysates and PGE2 accumulation in cultures of human granulosa-lutein cells. Dinoprostone 94-98 phospholipase A2 group IVA Homo sapiens 2-7 15878913-5 2005 Here we describe that AA induces expression of cytosolic phospholipase A2 (cPLA2) in a dose-dependent manner and that this upregulation is dependent upon downstream synthesis of PGE2. Dinoprostone 178-182 phospholipase A2 group IVA Homo sapiens 47-73 15878913-5 2005 Here we describe that AA induces expression of cytosolic phospholipase A2 (cPLA2) in a dose-dependent manner and that this upregulation is dependent upon downstream synthesis of PGE2. Dinoprostone 178-182 phospholipase A2 group IVA Homo sapiens 75-80 15668944-7 2005 Our results revealed that the cPLA(2) specific inhibitor, arachidonyl trifluoromethyl ketone (AACOCF(3)), blocked NO-induced eicosanoid production, while the presence of arachidonic acid enhanced the ability of the cells to make prostaglandin E(2) (PGE(2)). Dinoprostone 229-247 phospholipase A2 group IVA Homo sapiens 30-37 15477758-4 2004 Production of the COX product, prostaglandin E2, correlated with expression of cPLA2 and COX-2 and was blocked by non-steroidal anti-inflammatory drugs (NSAIDs, indomethacin or NS398). Dinoprostone 31-47 phospholipase A2 group IVA Homo sapiens 79-84 16299051-9 2006 mPGES induction and, possibly, cPLA2 induction appear to cooperate with COX-2 to determine IL-1beta-mediated PGE2 production in human ASM cells. Dinoprostone 109-113 phospholipase A2 group IVA Homo sapiens 31-36 16467083-0 2006 Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells. Dinoprostone 88-104 phospholipase A2 group IVA Homo sapiens 51-77 16467083-2 2006 We addressed whether HIPK2 restrains colon tumorigenesis by turning off cytosolic phospholipase A2 (cPLA2)-dependent prostaglandin E2 (PGE2) generation in the light of overwhelming evidence suggesting the contribution of this prostanoid in a variety of cancers. Dinoprostone 117-133 phospholipase A2 group IVA Homo sapiens 72-98 16467083-2 2006 We addressed whether HIPK2 restrains colon tumorigenesis by turning off cytosolic phospholipase A2 (cPLA2)-dependent prostaglandin E2 (PGE2) generation in the light of overwhelming evidence suggesting the contribution of this prostanoid in a variety of cancers. Dinoprostone 117-133 phospholipase A2 group IVA Homo sapiens 100-105 16467083-2 2006 We addressed whether HIPK2 restrains colon tumorigenesis by turning off cytosolic phospholipase A2 (cPLA2)-dependent prostaglandin E2 (PGE2) generation in the light of overwhelming evidence suggesting the contribution of this prostanoid in a variety of cancers. Dinoprostone 135-139 phospholipase A2 group IVA Homo sapiens 72-98 16467083-2 2006 We addressed whether HIPK2 restrains colon tumorigenesis by turning off cytosolic phospholipase A2 (cPLA2)-dependent prostaglandin E2 (PGE2) generation in the light of overwhelming evidence suggesting the contribution of this prostanoid in a variety of cancers. Dinoprostone 135-139 phospholipase A2 group IVA Homo sapiens 100-105 16467083-7 2006 RESULTS: HIPK2 silencing was associated with rousing PGE2 biosynthesis that was profoundly suppressed by the cPLA2 inhibitor. Dinoprostone 53-57 phospholipase A2 group IVA Homo sapiens 109-114 16467083-11 2006 CONCLUSIONS: Our findings reveal the novel mechanism of HIPK2 to restrain progression of human colon tumorigenesis, at least in part, by turning off cPLA2-dependent PGE2 generation. Dinoprostone 165-169 phospholipase A2 group IVA Homo sapiens 149-154 16153673-0 2005 RSV-induced prostaglandin E2 production occurs via cPLA2 activation: role in viral replication. Dinoprostone 12-28 phospholipase A2 group IVA Homo sapiens 51-56 16153673-5 2005 Specific inhibitors of cPLA2 significantly block RSV-induced PGE2 secretion, indicating a key role of cPLA2 in viral-induced PG production. Dinoprostone 61-65 phospholipase A2 group IVA Homo sapiens 23-28 15187863-7 2004 Because cytosolic phospholipase-A2 and secretory phospholipase-A2 are involved in the production of prostaglandin-E2 and other inflammatory mediators, this study suggests that regulation of phospholipase-A2 expression level may be an alternative approach to control in vivo tendon inflammation. Dinoprostone 100-116 phospholipase A2 group IVA Homo sapiens 8-34 15123778-0 2004 Cytosolic phospholipase A2 is responsible for prostaglandin E2 and leukotriene B4 formation in phagocyte-like PLB-985 cells: studies of differentiated cPLA2-deficient PLB-985 cells. Dinoprostone 46-62 phospholipase A2 group IVA Homo sapiens 0-26